Indicated for the treatment of mild to moderate dementia of the Alzheimer's type

Indicated for the treatment of Alzheimer's disease. Treatment with Kisunla should be initiated in patient with mild cognitive impairment or mild dementia stage of disease, the population in which the treatment was initiated in the clinical trials

Indicated for the treatment of moderate to severe dementia of the Alzheimer’s type in patients stabilized on 10 mg of donepezil hydrochloride once daily

Indicated for the treatment of Alzheimer’s in patients with mild cognitive impairment or mild dementia sage of the disease

Indicated for the treatment of mild-to-severe dementia of the Alzheimer’s type. This product is the first transdermal patch for this indication.

A first-of-its-kind, biologic treatment for Alzheimer’s disease. This drug is the first new Alzheimer’s drug since 2003